The impact of margin status on resection of primary pancreatic neuroendocrine tumors has been poorly defined. The objectives of the present study were to determine the impact of margin status on long-term survival of patients with pancreatic neuroendocrine tumors after curative resection and evaluate the impact of reresection to obtain a microscopically negative margin.
Patients who underwent curative-intent resection for pancreatic neuroendocrine tumors between 2000 and 2016 were identified at 8 hepatobiliary centers. Overall and recurrence-free survival were analyzed relative to surgical margin status using univariable and multivariable analyses.
Among 1,020 patients, 866 (84.9%) had an R0 (>1 mm margin) resection, whereas 154 (15.1%) had an R1 (≤1 mm margin) resection. R1 resection was associated with a worse recurrence-free survival (10-year recurrence-free survival, R1 47.3% vs R0 62.8%, hazard ratio 1.8, 95% confidence interval 1.2–2.7, P = .002); residual tumor at either the transection margin (R1t) or the mobilization margin (R1m) was associated with increased recurrence versus R0 (R1t versus R0: hazard ratio 1.8, 95% confidence interval 1.0–3.0, P = .033; R1m versus R0: hazard ratio 1.3, 95% confidence interval 1.0–1.7, P = .060). In contrast, margin status was not associated with overall survival (10-year overall survival, R1 71.1% vs R0 71.8%, P = .392). Intraoperatively, 539 (53.6%) patients had frozen section evaluation of the surgical margin; 49 (9.1%) patients had a positive margin on frozen section analysis; 38 of the 49 patients (77.6%) had reresection, and a final R0 (secondary R0) margin was achieved in 30 patients (78.9%). Extending resection to achieve an R0 status remained associated with worse overall survival (hazard ratio 3.1, 95% confidence interval 1.6–6.2, P = .001) and recurrence-free survival (hazard ratio 2.6, 95% confidence interval 1.4–5.0, P = .004) compared with primary R0 resection. On multivariable analyses, tumor-specific factors, such as cellular differentiation, perineural invasion, Ki-67 index, and major vascular invasion, rather than surgical margin, were associated with long-term outcomes.
Margin status was not associated with long-term survival. The reresection of an initially positive surgical margin to achieve a negative margin did not improve the outcome of patients with pancreatic neuroendocrine tumors. Parenchymal-sparing pancreatic procedures for pancreatic neuroendocrine tumors may be appropriate when feasible.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Surgery
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Clinical course of neuroendocrine tumors with different origins (the pancreas, gastrointestinal tract, and lung).Am J Clin Oncol. 2012; 35: 549-556
- Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors: an analysis of the U.S. Neuroendocrine Tumor Study Group.J Surg Oncol. 2018; 117: 868-878
- Long-term outcomes of gastroenteropancreatic neuroendocrine tumors.Pancreas. 2018; 47: 321-325
- Nonfunctional pancreatic neuroendocrine tumors.Surg Clin North Am. 2014; 94: 689-708
- National Rise of primary pancreatic carcinoid tumors: comparison to functional and nonfunctional pancreatic neuroendocrine tumors.J Am Coll Surg. 2017; 224: 1057-1064
- ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors.Neuroendocrinology. 2016; 103: 153-171
- Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS).Surgery. 2014; 155: 977-988
- Pancreatic cancer surgery: the new R-status counts.Ann Surg. 2017; 265: 565-573
- Survival after pancreaticoduodenectomy is not improved by extending resections to achieve negative margins.Ann Surg. 2009; 250: 76-80
- R0 versus R1 resection matters after pancreaticoduodenectomy, and less after distal or total pancreatectomy for pancreatic cancer.Ann Surg. 2017; https://doi.org/10.1097/SLA.0000000000002345
- Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.Ann Surg. 2007; 246: 52-60
- The importance of surgical margins in pancreatic cancer.J Surg Oncol. 2016; 113: 283-288
- The prognostic influence of resection margin clearance following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.J Gastrointest Surg. 2013; 17: 511-521
- Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patients.Ann Surg. 2014; 260 (discussion 3): 494-501
- Impact of intraoperative re-resection to achieve R0 status on survival in patients with pancreatic cancer: a single-center experience with 483 patients.Ann Surg. 2017; 265: 1219-1225
- Standards and minimum datasets for reporting cancers. Minimum dataset for the histopathological reporting of pancreatic, ampulla of vater and bile duct carcinoma. The Royal College of Pathologists, London2002
- Nomogram individually predicts the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms.Br J Cancer. 2017; 117: 1544-1550
- Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.Chin J Cancer. 2017; 36: 51
- Characteristics of 10-year survivors of pancreatic ductal adenocarcinoma.JAMA Surg. 2015; 150: 701-710
- Pancreatic cancer surgery in the new millennium: better prediction of outcome.Ann Surg. 2011; 254: 311-319
- Resection margins in pancreatic cancer.Surg Clin North Am. 2013; 93: 647-662
- Most pancreatic cancer resections are R1 resections.Ann Surg Oncol. 2008; 15: 1651-1660
- Surgical management of pancreatic neuroendocrine tumors.Surg Clin North Am. 2016; 96: 1447-1468
- Redefining the R1 resection in pancreatic cancer.Br J Surg. 2006; 93: 1232-1237
- Perineural invasion and associated pain in pancreatic cancer.Nat Rev Cancer. 2011; 11: 695-707
- A new scoring system to predict recurrent disease in grade 1 and 2 nonfunctional pancreatic neuroendocrine tumors.Ann Surg. 2018; 267: 1148-1154
- Consensus guidelines for the management and treatment of neuroendocrine tumors.Pancreas. 2013; 42: 557-577
- Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial.Ann Surg. 2001; 234: 758-768
Pitt SC, Pitt HA, Baker MS, Christians K, Touzios JG, Kiely JM, et al. Small pancreatic and periampullary neuroendocrine tumors: resect or enucleate? J Gastrointest Surg2009;13:1692-8.
- Pancreatic endocrine tumors less than 4 cm in diameter: resect or enucleate? A single-center experience.Pancreas. 2010; 39: 825-828
- Enucleation in pancreatic surgery: indications, technique, and outcome compared to standard pancreatic resections.Langenbecks Arch Surg. 2011; 396: 1197-1203
- Parenchyma-preserving resections for small nonfunctioning pancreatic endocrine tumors.Ann Surg Oncol. 2010; 17: 1621-1627
Published online: September 29, 2018
Accepted: August 8, 2018
Received in revised form: August 1, 2018
Received: April 24, 2018
Xu-Feng Zhang was supported by the Clinical Research Award of the First Affiliated Hospital of Xi'an Jiaotong University of China (No. XJTU1AF-CRF-2017-004).
© 2018 Elsevier Inc. All rights reserved.